Zhejiang Garden Biopharmaceutical Co.,Ltd. (SHE:300401)
China
· Delayed Price · Currency is CNY 15.60
+0.21 (1.36%)
Mar 10, 2026, 3:04 PM CST
SHE:300401 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,219 | 1,221 | 1,082 | 1,397 | 1,107 | 650.39 | Upgrade
|
| Other Revenue | 22.45 | 22.45 | 12.93 | 20.39 | 9.75 | 9.05 | Upgrade
|
| Revenue | 1,241 | 1,243 | 1,095 | 1,418 | 1,117 | 659.44 | Upgrade
|
| Revenue Growth (YoY) | 9.43% | 13.58% | -22.78% | 26.89% | 69.40% | -8.21% | Upgrade
|
| Cost of Revenue | 546.12 | 519.59 | 441.4 | 486.37 | 350.66 | 281.47 | Upgrade
|
| Gross Profit | 695.27 | 723.7 | 653.25 | 931.14 | 766.44 | 377.97 | Upgrade
|
| Selling, General & Admin | 263.14 | 308.87 | 378.77 | 444.55 | 257.61 | 93.3 | Upgrade
|
| Research & Development | 71.33 | 83.78 | 90.91 | 70.34 | 59.28 | 45.09 | Upgrade
|
| Other Operating Expenses | 21.17 | 13.24 | 16.44 | 16.24 | 3.48 | 5.61 | Upgrade
|
| Operating Expenses | 356.92 | 407.87 | 483.74 | 533.66 | 320.69 | 144.04 | Upgrade
|
| Operating Income | 338.35 | 315.83 | 169.51 | 397.48 | 445.75 | 233.93 | Upgrade
|
| Interest Expense | -31 | -35.63 | -38.41 | -21.82 | -10.81 | -16.91 | Upgrade
|
| Interest & Investment Income | 9.28 | 11.01 | 20.54 | 13.75 | 32.49 | 26.87 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.31 | 6.31 | 7.02 | 11.1 | -2.79 | -7.22 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.16 | -0.32 | -0.3 | -0.65 | -0.19 | -0.25 | Upgrade
|
| EBT Excluding Unusual Items | 321.78 | 297.19 | 158.36 | 399.86 | 464.46 | 236.42 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.88 | 0.25 | -0.34 | -2.83 | 0.4 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -3.78 | 31.53 | -0.04 | 17.8 | 76.22 | 0.02 | Upgrade
|
| Asset Writedown | -2.81 | -0.44 | -0.22 | -1.01 | -0.09 | -0.43 | Upgrade
|
| Other Unusual Items | 36.19 | 30.17 | 53.27 | 28.67 | 48.38 | 51.7 | Upgrade
|
| Pretax Income | 354.26 | 358.69 | 211.04 | 442.48 | 589.37 | 287.71 | Upgrade
|
| Income Tax Expense | 52.47 | 49.48 | 18.7 | 58.76 | 75.42 | 27.09 | Upgrade
|
| Earnings From Continuing Operations | 301.8 | 309.21 | 192.35 | 383.72 | 513.94 | 260.62 | Upgrade
|
| Minority Interest in Earnings | 0.01 | 0 | - | - | -30.18 | 2.6 | Upgrade
|
| Net Income | 301.8 | 309.21 | 192.35 | 383.72 | 483.77 | 263.22 | Upgrade
|
| Net Income to Common | 301.8 | 309.21 | 192.35 | 383.72 | 483.77 | 263.22 | Upgrade
|
| Net Income Growth | 5.94% | 60.76% | -49.87% | -20.68% | 83.79% | -23.42% | Upgrade
|
| Shares Outstanding (Basic) | 548 | 542 | 550 | 548 | 544 | 506 | Upgrade
|
| Shares Outstanding (Diluted) | 581 | 595 | 601 | 548 | 544 | 506 | Upgrade
|
| Shares Change (YoY) | -9.28% | -1.07% | 9.65% | 0.85% | 7.38% | 6.04% | Upgrade
|
| EPS (Basic) | 0.55 | 0.57 | 0.35 | 0.70 | 0.89 | 0.52 | Upgrade
|
| EPS (Diluted) | 0.52 | 0.52 | 0.32 | 0.70 | 0.89 | 0.52 | Upgrade
|
| EPS Growth | 16.77% | 62.50% | -54.29% | -21.35% | 71.15% | -27.78% | Upgrade
|
| Free Cash Flow | 103.29 | -13.97 | -84.57 | -2.89 | -203.33 | -166.46 | Upgrade
|
| Free Cash Flow Per Share | 0.18 | -0.02 | -0.14 | -0.01 | -0.37 | -0.33 | Upgrade
|
| Dividend Per Share | 0.114 | 0.114 | 0.071 | 0.140 | 0.188 | 0.103 | Upgrade
|
| Dividend Growth | 60.56% | 60.56% | -49.29% | -25.53% | 82.52% | - | Upgrade
|
| Gross Margin | 56.01% | 58.21% | 59.68% | 65.69% | 68.61% | 57.32% | Upgrade
|
| Operating Margin | 27.26% | 25.40% | 15.48% | 28.04% | 39.90% | 35.47% | Upgrade
|
| Profit Margin | 24.31% | 24.87% | 17.57% | 27.07% | 43.31% | 39.91% | Upgrade
|
| Free Cash Flow Margin | 8.32% | -1.12% | -7.72% | -0.20% | -18.20% | -25.24% | Upgrade
|
| EBITDA | 510.53 | 471.35 | 302.82 | 458.27 | 490.2 | 279.59 | Upgrade
|
| EBITDA Margin | 41.13% | 37.91% | 27.66% | 32.33% | 43.88% | 42.40% | Upgrade
|
| D&A For EBITDA | 172.18 | 155.52 | 133.31 | 60.79 | 44.45 | 45.66 | Upgrade
|
| EBIT | 338.35 | 315.83 | 169.51 | 397.48 | 445.75 | 233.93 | Upgrade
|
| EBIT Margin | 27.26% | 25.40% | 15.48% | 28.04% | 39.90% | 35.47% | Upgrade
|
| Effective Tax Rate | 14.81% | 13.80% | 8.86% | 13.28% | 12.80% | 9.41% | Upgrade
|
| Revenue as Reported | 1,241 | 1,243 | 1,095 | 1,418 | 1,117 | 659.44 | Upgrade
|
| Advertising Expenses | - | 2.37 | 0.97 | 0.7 | 0.8 | 1.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.